Adverse event reports following yellow fever vaccination (Q34013868)

30 July 2017

Adverse event reports following yellow fever vaccination (English)

1 reference

30 July 2017

0 references

1 reference

11

J Erin Staples

1 reference

30 July 2017

6

Nina Marano

1 reference

30 July 2017

1

Nicole P Lindsey

1 reference

30 July 2017

9

Gary W Brunette

1 reference

30 July 2017

Betsy A Schroeder

2

1 reference

30 July 2017

Elaine R Miller

3

1 reference

30 July 2017

M Miles Braun

4

1 reference

30 July 2017

Alison F Hinckley

5

1 reference

30 July 2017

Barbara A Slade

7

1 reference

30 July 2017

Elizabeth D Barnett

8

1 reference

30 July 2017

Katherine Horan

10

1 reference

30 July 2017

Phyllis E Kozarsky

12

1 reference

30 July 2017

Edward B Hayes

13

1 reference

30 July 2017

language of work or name

English

0 references

publication date

20 September 2008

1 reference

30 July 2017

1 reference

30 July 2017

26

1 reference

30 July 2017

48

1 reference

30 July 2017

6077-6082

1 reference

Comparison of the immunogenicity and safety of two 17D yellow fever vaccines.

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Anaphylaxis from yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

History of thymoma and yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Understanding vaccine safety information from the Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Rare case of fatal yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Effects of yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Effects of yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Effects of yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Risk of fatal adverse events associated with 17DD yellow fever vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Yellow fever-associated viscerotropic disease in Barcelona, Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

Prevention of yellow fever in persons traveling to the tropics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

The reporting sensitivities of two passive surveillance systems for vaccine adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.009

10.1016/J.VACCINE.2008.09.009

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference